TNXP
TNXP
NASDAQ · Biotechnology

Tonix Pharmaceuticals Holdin

$16.34
+1.39 (+9.30%)
As of Feb 8, 2:05 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 84.57M 86.26M 76.53M
Net Income -20,699,385 -25,319,011 -23,908,785
EPS
Profit Margin -24.5% -29.4% -31.2%
Rev Growth +3.2% +20.0% +0.5%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 97.43M 108.81M 97.98M
Total Equity 167.70M 160.32M 155.36M
D/E Ratio 0.58 0.68 0.63
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -24,990,141 -25,196,528 -24,930,968
Free Cash Flow -20,292,095 -20,848,476 -17,728,438